allogeneic dendritic cells
Vaccineexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00001064)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogeneic dendritic cells
- allogenic dendritic cells
- donor dendritic cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03726307 | Phase 1 | Apr 10, 2019 | National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
| NCT01525017 | Phase 1 | Feb 1, 2012 | Immunicum AB, Uppsala University |
| NCT00476177 | Phase 1 | Jul 1, 2003 | Harvard University, National Cancer Institute (NCI) |
| NCT00050323 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2002 | Genzyme |
| NCT00001064 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 1999 |
| Genzyme | For profit | 1 | 1 | 1 | 2002 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Immunicum AB | For profit | 1 | 1 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2012 |
7 organizations
Page 1 / 1